Retatrutide Dosing and Protocol: A 2026 UK Research Reference for Reconstitution, Titration, Storage and Study Design

Last updated: April 2026 · UK research-grade reference · For laboratory research use only — not for human consumption

Table of Contents

• 1. Research-protocol framing for retatrutide
• 2. Phase 2 titration schedules — obesity, T2DM, MASLD
• 3. TRIUMPH Phase 3 protocols
• 4. Reconstitution — bacteriostatic water protocol
• 5. Storage and aliquoting for UK laboratory research
• 6. Study design considerations for preclinical work
• 7. Adjustments by research cohort
• 8. Titration strategies to manage GI tolerability signals
• 9. Co-interventions and washout considerations
• 10. How retatrutide protocols differ from tirzepatide and semaglutide
• 11. UK procurement and quality standards
• 12. Frequently asked questions
• 13. References

1. Research-protocol framing for retatrutide

Retatrutide (LY3437943) is Eli Lilly’s triple agonist of GLP-1, GIP and glucagon receptors, currently investigational in UK, EU and US jurisdictions and delivered subcutaneously weekly in clinical trials. For UK-based laboratory research — in vitro cell work, ex vivo tissue studies, or licensed animal protocols — the published trial dosing provides the primary reference for peptide preparation, titration, dose-response design and storage. Nothing in this guide is for human use; it is a research-protocol reference for scientists designing retatrutide studies within their approved research framework.

Protocol parameters that matter for laboratory work are: the target dose (Phase 2 doses were 1, 4, 8 or 12 mg weekly); the titration rate (4-week dose escalation steps); the vehicle (bacteriostatic water standard); the reconstitution concentration (commonly 2 mg/ml or 5 mg/ml); and storage stability (reconstituted peptide: 2-8°C for 2-4 weeks; lyophilised: 2-8°C or −20°C for long-term).

2. Phase 2 titration schedules — obesity, T2DM, MASLD

The published Phase 2 obesity trial used an escalation schedule designed to reach target doses of 1, 4, 8 or 12 mg weekly without triggering excessive GI-adverse-event discontinuation. The typical schedule by target dose:

Target 1 mg: 1 mg from week 1 (no escalation required for this arm).

Target 4 mg: 2 mg weekly for weeks 1-4, then 4 mg weekly from week 5 onward.

Target 8 mg: 2 mg weeks 1-4 → 4 mg weeks 5-8 → 6 mg weeks 9-12 → 8 mg from week 13. (Some participants used an alternative schedule: 2 → 4 → 8 mg with 4-week intervals.)

Target 12 mg: 2 mg weeks 1-4 → 4 mg weeks 5-8 → 8 mg weeks 9-12 → 12 mg from week 13. (Some arms stepped through 6 mg rather than jumping 4 → 8.)

The Phase 2 T2DM trial (NCT04867785) used similar schedules with a slightly slower approach to 12 mg, and the Phase 2 MASLD sub-study (Sanyal 2024) paralleled the obesity protocol. All trials used weekly subcutaneous delivery and rotated injection sites (abdomen, thigh, upper arm) in clinical administration — this corresponds in research protocols to equivalent weekly dosing paradigms in animal work under licence.

3. TRIUMPH Phase 3 protocols

The TRIUMPH Phase 3 programme (NCT05929079 and sisters) carried forward the titration principle with minor refinements:

• TRIUMPH-1 (obesity without T2DM): target doses 1, 4, 8, 12 mg with 4-week escalation through 2 mg and 4 mg intermediate steps for the higher target arms. 80-week primary endpoint.
• TRIUMPH-3 (T2DM): target doses 0.5, 2, 4, 8, 12 mg — adding a lower 0.5 mg arm to calibrate the floor of the glycemic dose-response.
• TRIUMPH-4 (MASH biopsy-endpoint): 2 mg, 8 mg, 12 mg only, with biopsy at baseline and end-of-treatment.
• TRIUMPH-Outcomes (CVOT): flexible titration to tolerated maximum within 1-12 mg, reflecting pragmatic clinical use.

The consistent feature across TRIUMPH protocols is 4-week escalation intervals. Compressing titration below 4 weeks produces higher GI discontinuation rates based on Phase 2 observations; extending beyond 4 weeks delays target-dose studies without clear benefit.

4. Reconstitution — bacteriostatic water protocol

Retatrutide is supplied as a lyophilised peptide. For research reconstitution, the standard diluent is bacteriostatic water for injection (0.9% benzyl alcohol preserved water) because the benzyl alcohol preservative permits multi-dose extraction over several weeks at 2-8°C without microbial contamination risk. Sterile water is an alternative for single-use preparation but offers no preservation beyond immediate use.

Representative reconstitution worked example for a 10 mg vial:

• Withdraw 2 ml of bacteriostatic water into a syringe.
• Inject slowly down the inner wall of the vial — do not spray directly onto the lyophilised cake.
• Gently swirl (do not shake; shaking can denature peptides) until fully dissolved. This typically takes 30-60 seconds.
• Final concentration: 5 mg/ml (i.e., 1 mg per 0.2 ml or per 20 units on a standard U-100 insulin syringe).

For lower concentration work, reconstituting a 10 mg vial in 4 ml bacteriostatic water produces 2.5 mg/ml. A 2 mg/ml concentration (common for very small-volume research aliquots) uses 5 ml diluent in a 10 mg vial.

Reconstitution math table for a 10 mg vial:

• 1 ml diluent → 10 mg/ml → 1 mg per 10 units on a U-100 syringe
• 2 ml diluent → 5 mg/ml → 1 mg per 20 units
• 4 ml diluent → 2.5 mg/ml → 1 mg per 40 units
• 5 ml diluent → 2 mg/ml → 1 mg per 50 units

5. Storage and aliquoting for UK laboratory research

Storage recommendations for retatrutide in a UK research laboratory:

• Lyophilised peptide (unopened vials): 2-8°C for 2 years typical; −20°C for extended storage. Avoid repeated freeze-thaw of lyophilised peptide — it is stable in solid form but best practice is single-transfer-to-freezer then stable storage.
• Reconstituted peptide (bacteriostatic water): 2-8°C, protected from light. Stable for approximately 28 days in most research-grade peptide datasets — though stability is concentration-dependent and individual vial-batch stability should be verified against COA.
• Reconstituted peptide (sterile water, no preservative): Use same day; otherwise aliquot and freeze immediately at −20°C.
• Aliquoted peptide for freeze storage: split reconstituted vial into single-use aliquots in sterile microtubes; freeze at −20°C (−80°C preferred for long-term). Thaw once only per aliquot.

For UK laboratory workflows handling retatrutide across multi-week protocols, the pragmatic approach is: reconstitute in bacteriostatic water to 5 mg/ml, aliquot into single-week working volumes, store working vial at 2-8°C and remaining aliquots at −20°C. This minimises freeze-thaw cycles and maximises peptide integrity across a research protocol.

6. Study design considerations for preclinical work

Considerations specific to retatrutide preclinical design:

• Species selection: Rat and mouse models have been used extensively in pre-clinical retatrutide and dual-agonist work. Non-human primate work at Lilly informed the Phase 1 pharmacokinetic modelling (Coskun 2022).
• Dose scaling: Allometric scaling from human doses to rodent doses uses body-surface-area scaling conventions; human 12 mg/week is not directly translatable by body weight alone.
• Dose-response design: Phase 2 data suggest the dose-response is approximately linear across 1-12 mg in humans; preclinical study design should include ≥ 4 doses spanning 2 log-units to characterise the curve.
• Endpoint selection: The three most distinctive retatrutide effects to instrument are: (1) body weight and food intake; (2) hepatic triglyceride content and liver enzymes; (3) resting energy expenditure — the glucagon-driven EE signal is the distinctive mechanistic fingerprint relative to tirzepatide.
• Comparator arms: Including tirzepatide at matched dose as an active comparator allows the glucagon-agonism contribution to be isolated. Semaglutide as an additional comparator isolates the GIP contribution as well.

7. Adjustments by research cohort

Protocol adjustments by research objective:

Obesity / weight-loss focused: target dose of 8-12 mg in rodent-equivalent scaling, with 4-week escalation. Primary outcomes: weight change, food intake, body composition. Secondary: glucose homeostasis, lipids.

T2DM / glycemic focused: lower target doses (1-8 mg human-equivalent) are meaningful for glycemic endpoints even without maximal weight effect. Primary outcome: HbA1c equivalent or glucose tolerance test. Secondary: body weight.

MASLD / hepatic focused: 8-12 mg human-equivalent dosing produced maximal liver-fat reduction in Phase 2. Primary outcome: hepatic triglyceride content (by biochemistry or imaging equivalent). Secondary: liver enzymes, histology if terminal.

Energy expenditure / glucagon-specific: include resting metabolic rate / indirect calorimetry; the distinguishing phenotype of the glucagon-receptor contribution.

8. Titration strategies to manage GI tolerability signals

GI adverse events were the dominant tolerability signal in Phase 2 clinical retatrutide — most frequent in the first 12-16 weeks of dose escalation, decreasing substantially after target dose was achieved. Three titration strategies have emerged:

• Standard (Phase 2 protocol): 2 mg → 4 mg → 8 mg → 12 mg at 4-week intervals.
• Slow-titration: add 6 mg and 10 mg intermediate steps for participants with prior GI sensitivity — 2 → 4 → 6 → 8 → 10 → 12 mg at 4-week intervals (24-week titration).
• Stepped-hold: at any step where tolerability is challenging, remain at current dose for an additional 4 weeks before proceeding.

In research protocols mapping these to animal models, similar principles apply — gradual escalation improves acceptance of target dose without altering the eventual efficacy endpoint.

9. Co-interventions and washout considerations

Retatrutide’s pharmacology includes:

• Half-life: approximately 6 days (clinical trial PK), supporting weekly dosing.
• Steady state: reached after approximately 4 weeks of a fixed dose.
• Washout: 5 half-lives (~30 days) for near-complete drug clearance after cessation.

Research protocols running GLP-1 sequence or crossover designs should build in washout windows of ≥ 30 days when moving between retatrutide and other long-acting GLP-1-class molecules (semaglutide, tirzepatide) to avoid residual drug effect confounding the second arm.

10. How retatrutide protocols differ from tirzepatide and semaglutide

Side-by-side protocol summary:

• Semaglutide: target doses 0.25, 0.5, 1.0, 1.7, 2.4 mg weekly SC. 4-week titration. Half-life ~7 days.
• Tirzepatide: target doses 2.5, 5, 7.5, 10, 12.5, 15 mg weekly SC. 4-week titration. Half-life ~5 days.
• Retatrutide: target doses 1, 4, 8, 12 mg (Phase 2) and 0.5-12 mg (TRIUMPH) weekly SC. 4-week titration. Half-life ~6 days.

All three share the weekly SC rhythm and 4-week titration step size. Retatrutide’s dose range (1-12 mg) is the widest of the three in absolute mass terms, but all three produce comparable exposure per receptor occupancy in PK modelling.

11. UK procurement and quality standards

UK procurement requirements for research-grade retatrutide:

• Purity: ≥ 98% HPLC (≥ 99% is the emerging 2026 standard)
• Identity: MS confirmation per batch
• Content: nominal dose ± 5% tolerance
• Water and acetate content: < 10% water, acetate content declared
• Endotoxin: testing for research batches intended for cell culture or animal work
• Certificate of Analysis: batch-specific, dated, with lot number traceable to research records
• Dispatch: cold-chain, UK-address delivery, lyophilised form

See our Research-Grade Peptides Guide for the full standards specification, and our UK Research Peptide Buying Guide for sourcing due-diligence frameworks.

12. Frequently asked questions

What is the standard retatrutide reconstitution concentration in research protocols?

5 mg/ml (10 mg vial in 2 ml bacteriostatic water) is the most common research reconstitution ratio. 2 mg/ml and 2.5 mg/ml are used for very-small-volume or low-dose work.

How long is reconstituted retatrutide stable?

In bacteriostatic water at 2-8°C, approximately 28 days is the standard stability reference, though the batch-specific Certificate of Analysis from the supplier should be consulted.

Can retatrutide be reconstituted in sterile saline?

Sterile water for injection or bacteriostatic water are the standard diluents. Saline is occasionally used but introduces ionic interactions that may affect long-term peptide stability; it is not the default research choice.

What is the recommended titration interval?

Four weeks between dose steps, mirroring the Phase 2 and 3 clinical protocols. Shorter intervals increase GI adverse events; longer intervals delay protocol completion without clear benefit.

Which dose should be used as the research reference?

For general research-reference purposes, 8 mg was the middle-of-curve dose producing 94% of maximal 12 mg efficacy with lower GI burden in Phase 2. 12 mg is the maximum studied dose and the most frequently cited efficacy reference.

Is retatrutide stable at room temperature?

Lyophilised: yes, for several days — but not the long-term storage condition. Reconstituted: no — always store at 2-8°C after reconstitution.

How does the half-life of retatrutide affect research study windows?

Approximately 6-day half-life means steady state is reached after ~4 weeks of stable dosing, and washout to near-complete clearance requires 30+ days. Design research protocols accordingly.

13. References

1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med 2023;389:514-526.
2. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet 2023;402:529-544.
3. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for MASLD: a randomized phase 2a trial. Nature Medicine 2024;30:2037-2048.
4. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metab 2022;34:1234-1247.e9.
5. ClinicalTrials.gov: NCT04881760 (Phase 2 obesity), NCT04867785 (Phase 2 T2DM), NCT05929079 (TRIUMPH-1), NCT05929066 (TRIUMPH-3), NCT05882045 (TRIUMPH-4).
6. Eli Lilly retatrutide clinical trial protocols (as published in supplementary appendices of the NEJM and Lancet Phase 2 publications).
7. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205-216. (SURMOUNT-1 dosing reference)
8. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989-1002. (STEP-1 dosing reference)
9. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021;385:503-515. (SURPASS-2)
10. MHRA / UK Human Medicines Regulations 2012 — framework for research-grade peptide use in the UK (investigational status; not for human therapeutic use).

UK Research Cluster Hubs

• GLP-1 Peptides Complete Research Reference
• Retatrutide UK Research Guide
• Tirzepatide UK Research Guide
• BPC-157 UK Research Guide
• TB-500 UK Research Guide
• Research-Grade Peptides Standards Guide
• UK Research Peptide Buying Guide

Disclaimer: Retatrutide is an investigational peptide not approved for human use in the UK, EU or US. All products supplied by Peptides Lab UK are for licensed in vitro and ex vivo laboratory research purposes only. Not for human consumption, veterinary use, or any therapeutic application.